Navigation Links
Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
Date:12/19/2007

FDA Offers Special Protocol Assessment for Reviroc

AMSTERDAM, December 19 /PRNewswire/ -- Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.

The FDA meeting followed the successful completion of a multi centre phase II study for Reviroc showing an improved overall survival after autologous bone marrow transplantation in Non-Hodgkin's lymphoma patients. The phase III clinical trial design for Reviroc will focus on patients with Large B cell lymphoma. Kiadis Pharma anticipates filing of the IND, SPA request and Orphan Drug Designation application with the FDA within the next few weeks.

"We are very pleased with the outcome of the End of Phase II meeting with the FDA and with the possibility to access the FDA's Special Protocol Assessment program. Together with the strong support by our principal investigators we are well prepared to design a clear path towards marketing authorization for Reviroc," said Manja Bouman, CEO Kiadis Pharma.

About Reviroc

Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone-marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone mar
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... November 21, 2014 Prominent academics, ... will gather on December 3rd at Genetic Rx, ... series. GeneticRx will take place at the Joseph ... and will discuss the present and future of ... skipping, and gene editing—as well as the treatment ...
(Date:11/22/2014)... MD (PRWEB) November 21, 2014 ... management solutions provider, has released Limfinity® version 5.1.4. ... installation projects of Limfinity® than ever in RURO’s ... configuration and minority framework enhancement. Limfinity® version 5.1.4 ... far above and beyond bug fixes! , Limfinity® ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market ... (Metal, Glass, Plastic), by Application [GC, LC (HPLC, ... to 2018” analyses and studies the major market ... Europe, Asia, and Rest of the World. , ... spread through 135 pages and in-depth TOC on ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... Blacksburg, Va. Researchers at the Virginia Bioinformatics Institute ... guidelines that should help researchers in their efforts to ... The stakes are high: the concept of biological parts ... engineering are to be applied to biology. If successful, ...
... Mass., Aug. 8 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... to discuss its second quarter 2008 financial results and,to ... the,teleconference either by telephone or through a live web-cast. ... Date: Thursday, August 14, 2008, Time: 4:30 p.m. ...
... Aug. 8 MGT Capital Investments,Inc. (Amex: ... the Healthcare,Information Technology ("HCIT") sector, today reported financial ... and provided an update on,strategic milestones., Tim ... through,the first half of 2008 reflect continued progress ...
Cached Biology Technology:Tips on how to build a better home for biological parts 2Tips on how to build a better home for biological parts 3Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update 2MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 2MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 3MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 4MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 5
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/11/2014)... Inc., a Chicago -based digital forensics ... of Yaniv Schiff from Senior Computer Forensics ... role as Director, he will lead company efforts to ... provide leadership within the company,s digital forensics practice area.  ... Schiff joined Forensicon in 2006 and has ...
(Date:11/7/2014)... Leading Biometric companies aim to provide ... online transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... BABA ), Google Inc. (NASDAQ: GOOG ), Microsoft ... EBAY ) and MasterCard Inc. (NYSE: MA) ... biometric authentication company focused on the growing mobile commerce is ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... de Barcelona (UAB) has discovered the first scientific evidence of ... ancient Scythian warriors living over 2,000 years ago in the ... now, the results published in PLoS ONE indicate ... of Europeans, but to a demographic expansion of local Central ...
... wild pandas may need new dinner reservations and quickly ... off swaths of bamboo that pandas need to survive. ... , scientists from Michigan State University and the Chinese Academy ... affect the most common species of bamboo that carpet the ...
... Nobody knows the remarkable properties of human skin like ... our skin sensitive, sending the brain precise information about ... preserve a protective barrier against the world. Combining these ... exciting challenge for Stanford Chemical Engineering Professor Zhenan Bao ...
Cached Biology News:Mongolia and the Altai Mountains: Origins of genetic blending between Europeans and Asians 2Mongolia and the Altai Mountains: Origins of genetic blending between Europeans and Asians 3Climate change threatens giant pandas' bamboo buffet and survival 2Touch-sensitive plastic skin heals itself 2Touch-sensitive plastic skin heals itself 3
... human, mouse, and rat genes using ... siRNAs for a direct route to ... matching solutions for SYBR Green based ... and downstream analysis , Convenient ...
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... System, which processes two 96-well plates and tracks ... higher level of throughput to the CEQ product ... Coulters new GenomeLab family of products*, also offers ... liquid handers, for increased automation. The CEQ ...
... for proteomic scale kinase profiling, quantitative measurement ... research built on the flexible and powerful ... are available as part of our comprehensive ... Probe Content Our standard ...
Biology Products: